1. [CASE 1 — QUESTION 1] A 68-year-old woman with atrial fibrillation (AF, an irregular heart rhythm) maintained on warfarin (a vitamin K antagonist anticoagulant) with a consistently therapeutic INR (international normalized ratio, a measure of anticoagulant effect; target 2.0–3.0) presents to her rheumatologist with flare of osteoarthritis (OA, degenerative joint disease) affecting both knees. Her INR today is 2.4. She has no prior history of GI (gastrointestinal) ulcers or bleeding. Her eGFR (estimated glomerular filtration rate) is 62 mL/min/1.73m². She has a history of two prior myocardial infarctions (MIs, heart attacks) and is on aspirin 81 mg daily. The rheumatologist considers adding an oral NSAID (non-steroidal anti-inflammatory drug). Which of the following most accurately describes the mechanism by which adding any NSAID to this patient's warfarin and aspirin regimen increases her GI bleeding risk, and identifies the least hazardous oral NSAID choice given her cardiovascular history?

• A) The primary mechanism of increased GI bleeding with NSAID-warfarin combinations is pharmacokinetic: all NSAIDs are potent CYP2C9 (cytochrome P450 2C9, the liver enzyme that metabolizes S-warfarin) inhibitors that uniformly raise the INR to supratherapeutic levels within 48 to 72 hours; the least hazardous NSAID is celecoxib, because its COX-2 selectivity makes it the weakest CYP2C9 inhibitor among NSAIDs, producing the smallest INR elevation.
• B) Adding any NSAID increases GI bleeding risk through two pharmacodynamic mechanisms operating simultaneously: NSAID-induced GI mucosal erosions provide a bleeding site, and NSAID-mediated COX-1 inhibition impairs platelet TXA2 (thromboxane A2) synthesis, reducing platelet primary hemostasis at those sites; warfarin's impairment of secondary hemostasis (fibrin formation) compounds both risks multiplicatively; the least cardiovascularly hazardous oral NSAID for a patient with prior MI on aspirin is naproxen, which did not significantly increase major vascular events in the CNT meta-analysis, though PPI co-therapy and close INR monitoring remain mandatory.
• C) Adding an NSAID to warfarin increases GI bleeding exclusively through enhanced antiplatelet effect: NSAIDs irreversibly inhibit platelet COX-1 by the same covalent acetylation mechanism as aspirin, and adding NSAID therapy to this patient already on aspirin produces complete and permanent platelet inhibition that cannot be reversed; the safest NSAID is indomethacin, because its potent anti-inflammatory efficacy allows the shortest treatment duration and therefore the least cumulative platelet inactivation.
• D) The increased GI bleeding risk is caused exclusively by a pharmacokinetic interaction: NSAIDs reduce warfarin's renal tubular excretion by competing for OAT (organic anion transporter) proteins in the proximal tubule, causing warfarin accumulation and supratherapeutic anticoagulation; the safest oral NSAID is sulindac, because it undergoes the least renal OAT-mediated excretion and therefore interferes least with warfarin clearance.
• E) NSAID co-administration with warfarin increases GI bleeding through direct coagulation factor inhibition: NSAIDs suppress thrombopoietin (TPO, the hormone that stimulates platelet production from megakaryocytes) synthesis in the liver via COX-2 inhibition, reducing circulating platelet counts over 2 to 3 weeks; the resulting thrombocytopenia combined with anticoagulation produces the GI bleeding risk; the safest NSAID is celecoxib, as selective COX-2 inhibition causes the least hepatic TPO suppression.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. The rheumatologist prescribes naproxen 500 mg twice daily and a PPI (proton pump inhibitor, an acid-suppressing agent). Ten days later, the patient returns for routine INR monitoring. Her INR is now 4.3 (supratherapeutic; target 2.0–3.0). She has no active bleeding, no melena (black tarry stools), no hematemesis (vomiting blood), and no change in diet or other medications. She has been fully compliant with her warfarin at the same dose. Which of the following most accurately identifies the mechanism of her INR elevation and represents the most appropriate management?

• A) Her INR elevation is caused by naproxen-induced hepatotoxicity: naproxen's reactive acyl glucuronide metabolite (a toxic liver metabolite formed during naproxen breakdown) has caused hepatocellular injury that reduces synthesis of all hepatic proteins including albumin and vitamin K-dependent clotting factors; the appropriate management is immediate naproxen discontinuation and urgent liver biopsy to assess hepatic fibrosis before warfarin dose adjustment.
• B) Her INR elevation is caused by naproxen-mediated PPI displacement from plasma albumin binding sites, reducing PPI bioavailability and allowing excess gastric acid to degrade warfarin in the proximal small intestine before absorption, paradoxically increasing warfarin bioavailability by forcing faster gastric emptying; management is to change the PPI to a different formulation.
• C) Her INR elevation reflects normal pharmacokinetic variability and does not require any intervention; INR values between 3.0 and 5.0 in the absence of active bleeding are within the acceptable range of warfarin therapeutic monitoring and do not represent a clinically significant interaction with naproxen; monitoring should continue at the same 4-week interval.
• D) Naproxen has modest CYP2C9 inhibitory activity that can reduce the hepatic clearance of S-warfarin (the more pharmacologically active warfarin enantiomer, metabolized primarily by CYP2C9), raising warfarin plasma concentrations and the INR; in the absence of active bleeding, an INR of 4.3 is managed by holding one or two warfarin doses, administering low-dose oral vitamin K (1 to 2.5 mg) to lower the INR more rapidly, rechecking the INR in 24 to 48 hours, and restarting warfarin at a modestly reduced dose with more frequent INR monitoring while naproxen is continued.
• E) Her INR elevation is caused by naproxen's inhibition of intestinal P-glycoprotein (P-gp, a drug efflux transporter that limits warfarin absorption), doubling warfarin bioavailability after each dose; the appropriate management is to reduce the warfarin dose by exactly 50% to compensate for the doubled absorption, as this ratio remains constant throughout naproxen co-administration.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. Three months later, the patient's warfarin has been re-stabilized with an INR of 2.6. She calls her physician reporting two episodes of hematemesis (vomiting blood) and black tarry stools (melena) over the past 24 hours. She continues naproxen 500 mg twice daily, PPI once daily, aspirin 81 mg daily, and warfarin. Vital signs by phone: heart rate 108 bpm, blood pressure 102/68 mmHg. She feels lightheaded when standing. Which of the following most accurately identifies all the pharmacological mechanisms contributing to the severity of her GI hemorrhage, and represents the most critical immediate action?

• A) Three simultaneous hemostatic failure mechanisms are contributing: naproxen has caused GI mucosal erosions (providing the bleeding site) and reversibly inhibited platelet COX-1-dependent TXA2 synthesis (impairing primary hemostasis); aspirin has irreversibly inhibited any remaining platelet COX-1 (permanently disabling platelet TXA2 production for those platelets); and warfarin has impaired secondary hemostasis by reducing vitamin K-dependent clotting factor activity; the most critical immediate action is to direct her to the emergency department immediately, as her hemodynamic instability (tachycardia and orthostatic symptoms) indicates significant blood volume loss requiring urgent resuscitation, endoscopy, and consideration of warfarin reversal.
• B) The bleeding is caused exclusively by warfarin over-anticoagulation; naproxen and aspirin do not contribute to the severity because both agents affect only platelet primary hemostasis, which is redundant with the fibrin-based secondary hemostasis provided by warfarin; the most critical immediate action is to instruct the patient to hold her warfarin dose and recheck INR in 48 hours before deciding whether emergency care is needed.
• C) The primary mechanism is naproxen-induced selective COX-2 inhibition in the gastric mucosa that paradoxically upregulates leukotriene B4 (LTB4, a pro-inflammatory lipid mediator) synthesis, causing intense mucosal eosinophilic inflammation that erodes the mucosa independently of prostaglandin pathways; warfarin and aspirin are not contributing; management is cessation of naproxen and administration of a leukotriene receptor antagonist.
• D) The bleeding is caused by naproxen-mediated activation of the extrinsic coagulation cascade: naproxen's arachidonic acid metabolites activate tissue factor (TF, a protein that initiates the extrinsic coagulation pathway) on GI endothelial cells, generating thrombin that paradoxically consumes all clotting factors through a consumption coagulopathy; the appropriate immediate action is fresh frozen plasma (FFP) infusion to replace consumed clotting factors before endoscopy.
• E) Two mechanisms are contributing: naproxen's GI mucosal injury provides the bleeding site, and warfarin's anticoagulation prevents clot formation; aspirin's irreversible platelet inhibition is not additive because all platelets in this patient are already fully inhibited by naproxen; the most critical immediate action is administration of oral vitamin K 10 mg at home and outpatient INR recheck in 24 hours.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. She is admitted, resuscitated, and undergoes urgent upper endoscopy revealing two duodenal ulcers with a visible vessel (a sign of high re-bleeding risk). The ulcers are treated endoscopically. Warfarin is held and later restarted at a reduced dose. H. pylori testing is negative. Naproxen is permanently discontinued. She is discharged on high-dose PPI twice daily and returns to clinic 6 weeks later with stable INR 2.5, healed ulcers on repeat endoscopy, and recurrent bilateral knee pain that acetaminophen is not adequately controlling. Her cardiologist insists she remain on aspirin and warfarin indefinitely. Which of the following represents the most appropriate long-term analgesic strategy for her knee OA given her current risk profile?

• A) Resume naproxen 500 mg twice daily with twice-daily high-dose PPI, because naproxen has the best cardiovascular risk profile among NSAIDs and the PPI effectively neutralizes all GI bleeding risk including the interaction with warfarin and aspirin; the prior bleed was a one-time event and PPI co-therapy makes re-challenge with naproxen safe.
• B) Switch to celecoxib 200 mg twice daily without PPI, because its COX-2 selectivity eliminates all GI mucosal prostaglandin depletion and therefore provides complete GI protection regardless of concurrent warfarin and aspirin; celecoxib does not require PPI co-therapy when used in patients already on anticoagulation.
• C) Topical diclofenac 1% gel applied to both knees, with continuation of twice-daily PPI; topical diclofenac achieves systemic bioavailability of approximately 6 to 10% of an equivalent oral dose, substantially reducing GI mucosal prostaglandin depletion, platelet COX-1 inhibitory effect, and cardiovascular risk while delivering effective local analgesic and anti-inflammatory action to the knee joints; this strategy avoids the systemic pharmacodynamic contributions to GI bleeding and cardiovascular events that make oral NSAIDs particularly hazardous in this patient.
• D) Prescribe tramadol 50 mg three times daily as a long-term analgesic, because tramadol is the preferred analgesic for OA in elderly patients on anticoagulation, has no GI mucosal effects, and does not interact with warfarin, aspirin, or the cardiovascular medications; the American Geriatrics Society Beers Criteria specifically recommends tramadol as the first alternative when oral NSAIDs are contraindicated.
• E) Restart oral ibuprofen 200 mg as needed (maximum twice weekly) with ongoing PPI, because intermittent low-dose ibuprofen use does not significantly suppress mucosal prostaglandins at this dose and frequency, effectively eliminating the GI bleeding interaction with warfarin; the reversible platelet inhibition from ibuprofen at this dose is clinically negligible when dosed twice weekly.

5. [CASE 2 — QUESTION 1] A 55-year-old man with severe persistent asthma, chronic rhinosinusitis (long-standing sinus inflammation), and nasal polyposis (noncancerous nasal growths) presents to the emergency department with chest pain and an ECG (electrocardiogram, a test of heart electrical activity) showing ST-segment changes consistent with non-ST-elevation myocardial infarction (NSTEMI, a type of heart attack). The interventional cardiologist wants to initiate dual antiplatelet therapy (DAPT) with aspirin 325 mg plus ticagrelor (a P2Y12 receptor antagonist that blocks ADP-mediated platelet activation). The patient immediately states he cannot take aspirin — he has documented AERD (aspirin-exacerbated respiratory disease) with a prior emergency department visit for severe bronchospasm after aspirin. He has never been formally desensitized. Which of the following most accurately describes the pharmacological conflict in this clinical scenario?

• A) There is no pharmacological conflict: ticagrelor alone is equivalent to DAPT with aspirin plus ticagrelor for NSTEMI outcomes, because ticagrelor's P2Y12 receptor blockade produces more complete and sustained platelet inhibition than aspirin's COX-1 inhibition; aspirin can be permanently omitted without compromising antiplatelet efficacy in this patient.
• B) The conflict is easily resolved by substituting celecoxib for aspirin in the DAPT regimen: celecoxib provides antiplatelet activity equivalent to aspirin through selective COX-2 inhibition of platelet thromboxane synthesis, and does not trigger AERD because COX-1 remains uninhibited; celecoxib 200 mg daily plus ticagrelor is an established alternative to standard DAPT in AERD patients with ACS (acute coronary syndrome).
• C) The conflict is pharmacologically insignificant because AERD reactions to aspirin are limited to the respiratory mucosa and cannot occur when aspirin is given at the high loading dose (325 mg) used for NSTEMI; the large dose overwhelms the airway leukotriene response by producing complete COX-1 inhibition that paradoxically suppresses rather than stimulates leukotriene synthesis above a threshold dose.
• D) The conflict is resolved by using intravenous dipyridamole in place of aspirin: dipyridamole inhibits platelet aggregation through phosphodiesterase inhibition without any COX-1 activity and is pharmacologically equivalent to aspirin as the anchor agent in DAPT for NSTEMI; standard cardiological guidelines endorse dipyridamole as the first-line aspirin substitute in AERD patients with ACS.
• E) The conflict is real and pharmacologically significant: aspirin's irreversible COX-1 acetylation in the respiratory mucosa removes PGE2-mediated mast cell restraint and triggers cysteinyl leukotriene shunting, making aspirin contraindicated in AERD; however, aspirin is the cornerstone of DAPT for NSTEMI and cannot simply be replaced with an alternative antiplatelet agent without evidence of equivalent cardiovascular outcome benefit; the appropriate resolution is urgent aspirin desensitization performed in a monitored setting, which would enable both the cardiac indication and long-term AERD management benefit.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. The allergy/immunology team is consulted urgently and aspirin desensitization is initiated in the cardiac care unit with resuscitation capability. The procedure involves administering incrementally increasing aspirin doses, starting at 20 mg, with the patient observed between each dose escalation. At the 80 mg dose, he develops rhinorrhea, mild nasal congestion, and a 15% decrease in FEV1 (forced expiratory volume in one second, a measure of airway obstruction) from baseline. The team treats the reaction and the symptoms resolve. Dosing is then continued and advanced. He eventually tolerates 325 mg aspirin without reaction and is started on standard DAPT. Which of the following most accurately describes the pharmacological mechanism by which the reaction occurred at the 80 mg dose, and why the desensitization procedure is able to continue past the point of the reaction?

• A) The reaction at 80 mg occurred because 80 mg is the minimum dose required to fully saturate all platelet COX-1 binding sites, producing complete TXA2 depletion and triggering the airway response; once TXA2 is fully depleted, the leukotriene pathway automatically self-limits through negative feedback from TXA2 receptor downregulation, allowing the dose to be advanced without further reactions.
• B) The reaction at 80 mg was an IgE-mediated anaphylactic response to the aspirin dose; after the reaction resolved, the patient underwent rapid desensitization through tachyphylaxis (temporary unresponsiveness) of IgE receptors on mast cell surfaces; tachyphylaxis to aspirin IgE persists for approximately 6 hours, providing the window in which dosing can be advanced; after desensitization is complete, IgE receptors recover and daily aspirin is required to maintain tachyphylaxis.
• C) The reaction at 80 mg occurred because COX-1 inhibition at this dose removed sufficient PGE2-mediated mast cell restraint and redirected enough AA flux into the 5-LOX pathway to trigger a cysteinyl leukotriene surge; the procedure continues past the reaction because the same COX-1 inhibition that triggered the initial leukotriene burst also progressively desensitizes the leukotriene pathway — through mechanisms involving sustained downregulation of 5-LOX activity and LTC4 synthase expression — allowing the next dose to be tolerated with a diminished or absent leukotriene response; maintaining continuous aspirin keeps the pathway suppressed.
• D) The reaction at 80 mg represents an aspirin-specific pharmacokinetic threshold: at 80 mg, aspirin plasma concentrations first exceed the blood-brain barrier (BBB) penetration threshold and inhibit cyclooxygenase in central serotonergic neurons, causing a systemic release of serotonin that activates bronchial 5-HT2A receptors and triggers bronchoconstriction; advancing the dose is possible because central COX-1 is irreversibly inactivated after the 80 mg exposure and subsequent doses cannot cause further serotonin release.
• E) The reaction at 80 mg occurred because aspirin acetylated COX-2 in airway epithelial cells, shifting arachidonic acid metabolism toward 15-HETE (15-hydroxyeicosatetraenoic acid, an anti-inflammatory lipid mediator) rather than PGE2; 15-HETE paradoxically activates cysteinyl leukotriene receptors on airway smooth muscle at this transition dose; at doses above 160 mg, aspirin's COX-1 inhibition dominates COX-2 inhibition and 15-HETE production falls, explaining why higher doses are better tolerated.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. Six months after successful desensitization, the patient is tolerating daily aspirin 81 mg (maintained from his DAPT course) without any respiratory symptoms. His nasal polyp burden (noncancerous nasal growths) has visibly reduced and his sense of smell has markedly improved. He now presents to his primary care physician with tension headache and asks whether he can take ibuprofen 400 mg for the headache. His physician, unfamiliar with the scope of AERD desensitization, is uncertain whether ibuprofen tolerance is included in his aspirin desensitization. Which of the following most accurately explains whether this patient can take ibuprofen and why?

• A) He cannot take ibuprofen because his aspirin desensitization produced tolerance exclusively to aspirin molecules — the desensitization procedure works by generating aspirin-specific IgG4 blocking antibodies (protective antibodies that prevent aspirin from triggering mast cell degranulation), and these antibodies are structurally specific to aspirin and do not cross-react with ibuprofen's different chemical scaffold.
• B) He can take ibuprofen because aspirin desensitization produces tolerance to the class-wide pharmacological effect of COX-1 inhibition — not to aspirin specifically as a chemical entity; the AERD reaction mechanism requires COX-1 inhibition to trigger leukotriene shunting, and the desensitization-induced downregulation of the 5-LOX pathway and LTC4 synthase activity means any COX-1 inhibitor including ibuprofen will now be tolerated; this class-wide tolerance persists as long as he maintains his daily aspirin without gaps exceeding 72 hours.
• C) He cannot take ibuprofen because ibuprofen, unlike aspirin, is a selective COX-2 inhibitor that triggers AERD reactions through a different mechanism — COX-2 inhibition in bronchial epithelial cells upregulates 15-HETE production that directly activates airway mast cells independently of the leukotriene pathway; desensitization to aspirin's COX-1 effect provides no protection against ibuprofen's COX-2-mediated 15-HETE reaction.
• D) He can take ibuprofen only at doses below 200 mg because ibuprofen's AERD-triggering effect is dose-dependent with a threshold at 200 mg; aspirin desensitization provides partial dose-dependent tolerance that protects against reactions to doses below the threshold but not above; his daily aspirin dose of 81 mg maintains tolerance only up to an ibuprofen equivalent dose of 200 mg.
• E) He cannot take ibuprofen because ibuprofen competitively blocks aspirin's access to the platelet COX-1 active site, reversibly preventing aspirin acetylation and therefore destabilizing his desensitization-induced tolerance; taking ibuprofen would accelerate lapse of aspirin desensitization tolerance by interfering with the ongoing daily aspirin COX-1 acetylation required for maintenance.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. One year after desensitization, he undergoes elective knee replacement surgery. The surgical team holds all antiplatelet agents perioperatively per protocol, and he does not take aspirin for 5 days. On postoperative day 5, a nurse prepares to give him his usual aspirin 81 mg dose. The patient, knowing his AERD history, becomes concerned and asks whether he needs to be evaluated before restarting aspirin. The consulting allergist is called. Which of the following most accurately advises what should happen next and why?

• A) He can safely restart aspirin 81 mg immediately because 5 days without aspirin is within the maintenance window for desensitization-induced tolerance; tolerance to daily aspirin lasts approximately 2 weeks between doses before the leukotriene pathway recovers, so a 5-day perioperative hold does not cause tolerance lapse.
• B) He can restart aspirin 81 mg immediately because the surgical procedure itself maintained desensitization tolerance: general anesthesia produces systemic anti-inflammatory effects that suppress 5-LOX activity in airway mast cells, substituting for the aspirin-maintained COX-1 inhibition during the perioperative period and preserving AERD tolerance throughout the hold.
• C) He should be given a test dose of aspirin 10 mg and observed for 30 minutes; if no reaction occurs, full-dose aspirin can be restarted immediately, because residual aspirin-acetylated platelet COX-1 from before surgery provides partial tolerance protection for up to 7 to 10 days corresponding to the platelet lifespan.
• D) He should not restart aspirin 81 mg on postoperative day 5 without going through re-desensitization, because his desensitization-induced tolerance will have fully lapsed: tolerance requires continuous daily aspirin and dissipates within 72 hours of aspirin cessation; after 5 days without aspirin, his leukotriene pathway will have returned to its pre-desensitization overactive state; restarting full-dose aspirin without re-desensitization carries the risk of triggering a severe AERD reaction, including bronchospasm that could be particularly dangerous in the postoperative setting with impaired respiratory reserve.
• E) He should restart aspirin 81 mg immediately because his prior 1-year course of daily aspirin has produced permanent epigenetic changes (long-lasting modifications to gene expression without changing the DNA sequence) in airway mast cell precursors in the bone marrow, causing heritable permanent suppression of 5-LOX and LTC4 synthase expression in all newly produced mast cells regardless of subsequent aspirin interruptions.

9. [CASE 3 — QUESTION 1] A 74-year-old woman with hypertension managed on lisinopril 20 mg daily and hydrochlorothiazide (HCTZ, a thiazide diuretic) 25 mg daily, and CKD (chronic kidney disease) stage 3a (eGFR 58 mL/min/1.73m²) is prescribed diclofenac 75 mg twice daily by an orthopedic surgeon for hip osteoarthritis (OA, degenerative joint disease). She returns 2 weeks later with her daughter, who reports the patient has been more fatigued and less urinating than usual. Laboratory results: creatinine 2.9 mg/dL (baseline 1.3 mg/dL), potassium 5.9 mEq/L (normal 3.5–5.0 mEq/L), blood pressure 162/94 mmHg (baseline 128/80 mmHg on her current regimen). Urinalysis: no casts, no proteinuria. Which of the following most accurately describes all the mechanisms by which diclofenac has produced her three simultaneous adverse findings (AKI, hyperkalemia, and elevated blood pressure)?

• A) Three simultaneous mechanisms explain her presentation: (1) AKI — diclofenac's COX inhibition removes prostaglandin-mediated afferent arteriolar vasodilation; combined with lisinopril's blockade of angiotensin II-dependent efferent arteriolar constriction and HCTZ-induced volume depletion, all three GFR-maintaining compensatory mechanisms are simultaneously disabled (triple whammy); (2) hyperkalemia — diclofenac reduces prostaglandin-dependent renin release, lowering angiotensin II and aldosterone, reducing potassium excretion in the collecting duct; this adds to lisinopril's already established RAAS suppression; (3) blood pressure elevation — NSAID-mediated prostaglandin suppression enhances renal sodium reabsorption, increasing plasma volume and peripheral vascular resistance, directly counteracting lisinopril's and HCTZ's antihypertensive mechanisms.
• B) Only one mechanism explains her presentation: diclofenac is a potent CYP2C9 inhibitor that reduces hepatic clearance of lisinopril's active metabolite lisinoprilat, raising lisinopril plasma concentrations to nephrotoxic levels; the hyperkalemia, AKI, and blood pressure elevation all result from lisinopril accumulation rather than from diclofenac's intrinsic pharmacological effects; stopping diclofenac allows lisinopril levels to normalize.
• C) Two mechanisms explain her presentation: (1) diclofenac's reactive acyl glucuronide metabolite directly damages proximal tubular cells causing ATN (acute tubular necrosis, death of renal tubular cells), explaining the AKI and hyperkalemia from tubular K+ handling failure; (2) diclofenac's aldosterone receptor agonist properties in the adrenal cortex cause autonomous aldosterone secretion that paradoxically lowers renin while raising aldosterone, explaining the blood pressure elevation; the HCTZ and lisinopril are not contributory.
• D) Her presentation reflects HCTZ-induced electrolyte crisis: HCTZ has caused severe hypokalemia that triggered a compensatory renin-angiotensin-aldosterone response, raising blood pressure; the creatinine elevation reflects HCTZ-induced urinary sodium wasting causing severe prerenal azotemia; diclofenac is not contributory because its onset of renal prostaglandin suppression requires at least 6 weeks of use to become clinically significant.
• E) Her blood pressure elevation and AKI reflect a single mechanism: diclofenac-induced platelet TXA2 overproduction from unbalanced COX-2 inhibition (leaving COX-1-derived TXA2 unopposed) causes systemic vasoconstriction and renal afferent arteriolar constriction simultaneously; the hyperkalemia is a separate finding unrelated to NSAID use and represents lisinopril-induced type IV renal tubular acidosis that predated diclofenac initiation.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. Diclofenac is identified as the precipitating agent. The patient is clinically assessed: she is mildly volume-depleted with dry mucous membranes. Her potassium of 5.9 mEq/L requires monitoring given borderline hyperkalemia. Which of the following most accurately describes the appropriate acute management of her triple whammy AKI and the expected renal recovery trajectory?

• A) The appropriate management is immediate hemodialysis (a kidney replacement therapy) to rapidly reduce the potassium of 5.9 mEq/L, because triple whammy AKI from NSAIDs invariably progresses to require dialysis and early initiation prevents the need for emergent dialysis when potassium reaches 6.5 mEq/L; the creatinine of 2.9 mg/dL from a baseline of 1.3 mg/dL confirms irreversible structural renal damage requiring renal replacement therapy.
• B) The appropriate management is to stop diclofenac, continue lisinopril and HCTZ at full doses because stopping them would destabilize blood pressure control, and administer oral sodium polystyrene sulfonate (a potassium-binding resin) to reduce the potassium; renal recovery is expected in 2 to 4 weeks as the prostaglandin inhibition resolves but the GFR never fully returns to baseline in patients over 70.
• C) The appropriate management is to add spironolactone (a potassium-sparing aldosterone antagonist) to address the hyperkalemia by blocking aldosterone receptor-mediated sodium/potassium exchange, and continue all current medications while awaiting natural recovery; the AKI will resolve within 24 hours of diclofenac exposure ending because prostaglandin synthesis recovers immediately.
• D) The appropriate management is to start a high-dose corticosteroid (prednisone) course, because triple whammy AKI is an immune-mediated interstitial nephritis (kidney inflammation from immune activation) triggered by the diclofenac-lisinopril-HCTZ combination; corticosteroid therapy reduces tubulointerstitial inflammation and is required for renal recovery in patients over 65.
• E) The appropriate management is to stop diclofenac immediately, temporarily hold lisinopril and HCTZ to allow renal perfusion pressure and efferent arteriolar compensation to recover, administer IV normal saline to correct volume depletion (which removes the third component of the triple whammy), and monitor creatinine and potassium every 24 to 48 hours; hemodynamic AKI from triple whammy is typically reversible — creatinine usually returns to near-baseline within days to 1 to 2 weeks after drug discontinuation and volume repletion, provided no irreversible structural injury has occurred.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. Two weeks after stopping diclofenac and lisinopril, and receiving IV fluids, her creatinine has recovered to 1.5 mg/dL (close to her pre-event baseline of 1.3 mg/dL). Lisinopril has been cautiously restarted at a reduced dose. Blood pressure is 136/84 mmHg. She continues to report significant hip pain that acetaminophen is not adequately controlling. The orthopedist asks whether any NSAID can now be safely used. Which of the following most accurately describes the appropriate NSAID strategy for her hip OA?

• A) Oral diclofenac 50 mg twice daily (a reduced dose from the prior 75 mg twice daily) can be safely restarted because at half the prior dose, renal prostaglandin suppression is reduced by approximately 50%, bringing her risk to an acceptable level; eGFR of 58 mL/min/1.73m² (stage 3a CKD) does not contraindicate oral NSAID use at reduced doses.
• B) Oral celecoxib 100 mg daily is the appropriate choice because its selective COX-2 inhibition spares renal COX-1 prostaglandins responsible for maintaining GFR, making it renal-safe in CKD stage 3a; celecoxib does not interact with lisinopril through the prostaglandin mechanism because it does not inhibit the COX-1 isoform expressed in renal afferent arteriolar smooth muscle cells.
• C) Topical diclofenac 1% gel applied to the hip region, with continued PPI gastroprotection; at systemic bioavailability of approximately 6 to 10% of an oral equivalent, topical diclofenac provides effective local analgesia and anti-inflammation at the joint while substantially reducing systemic renal prostaglandin suppression and minimizing reconstitution of the triple whammy combination; close monitoring of renal function and blood pressure is still appropriate given her recent episode and ongoing ACE inhibitor use.
• D) No NSAID in any formulation is safe for this patient given her recent triple whammy AKI; all NSAIDs including topical formulations are absolutely contraindicated for life in patients with prior triple whammy episodes because they are at permanent high risk of recurrence regardless of drug dose, route, or formulation.
• E) Oral naproxen 250 mg twice daily with PPI is the most appropriate oral NSAID because naproxen's favorable cardiovascular risk profile (it did not increase major vascular events in the CNT meta-analysis) extends to renal safety, making it safer than diclofenac or ibuprofen in patients with CKD and concurrent ACE inhibitor therapy; the prior triple whammy with diclofenac was agent-specific and would not recur with naproxen.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. During her follow-up care, the managing physician wants to counsel her that if she ever requires an oral analgesic for a future acute pain episode, she should be aware that almost any systemic NSAID would likely raise her blood pressure by 5 to 8 mmHg or more. She asks which of her antihypertensive medications is least likely to have its effect blunted by NSAIDs, in case the cardiologist ever changes her regimen. Which of the following correctly identifies which antihypertensive class is most resistant to NSAID-mediated attenuation and explains why?

• A) ACE inhibitors (such as lisinopril) are most resistant to NSAID interaction because ACE inhibitors work by increasing bradykinin levels; NSAIDs do not affect bradykinin synthesis or degradation, so the vasodilatory effect of elevated bradykinin is preserved regardless of NSAID use; the blood pressure effect of ACE inhibitors is therefore independent of prostaglandin pathways.
• B) Calcium channel blockers (such as amlodipine) are most resistant to NSAID-mediated blood pressure attenuation because their antihypertensive mechanism — direct inhibition of L-type voltage-gated calcium channels in vascular smooth muscle — does not depend on prostaglandin pathways or renal sodium handling; NSAIDs cannot override vasodilation achieved by blocking calcium-dependent vascular smooth muscle contraction.
• C) Thiazide diuretics (such as HCTZ) are most resistant to NSAID attenuation because thiazide-induced natriuresis (urinary sodium excretion) operates through direct inhibition of the Na-Cl cotransporter in the distal convoluted tubule; since NSAIDs primarily suppress prostaglandins in the proximal tubule and loop of Henle, thiazide-mediated distal tubule sodium excretion is pharmacologically insulated from NSAID interference.
• D) Beta-blockers (such as metoprolol) are most resistant to NSAID attenuation because beta-blockers lower blood pressure primarily by reducing heart rate and cardiac output through beta-1 adrenergic receptor blockade; NSAIDs cannot counteract the negative chronotropic effect of beta-blockers because reduced heart rate does not depend on prostaglandin-mediated vascular tone.
• E) ARBs (angiotensin receptor blockers, such as losartan) are most resistant to NSAID attenuation because ARBs block AT1 (angiotensin type 1) receptors directly at the vascular smooth muscle cell, bypassing the prostaglandin-renin axis; NSAIDs can suppress prostaglandin-dependent renin release but cannot override the direct AT1 receptor blockade provided by ARBs, making the ARB antihypertensive effect independent of NSAID-mediated renin changes.

13. [CASE 4 — QUESTION 1] A 32-year-old woman at 30 weeks of gestation presents to her obstetrician for a routine prenatal visit. One week earlier she visited an urgent care clinic for low back pain and was given ibuprofen 400 mg three times daily without disclosure of her pregnancy. She took ibuprofen for 7 days. Routine obstetric ultrasound today shows an amniotic fluid index (AFI, a measure of total amniotic fluid volume) of 4.1 cm (oligohydramnios defined as AFI below 5 cm; normal range 8–18 cm). Fetal cardiac Doppler (ultrasound assessment of fetal blood flow) shows early constriction (narrowing) of the ductus arteriosus (DA, the fetal blood vessel that normally bypasses the lungs). The fetus is otherwise appropriately grown with normal biometry (measurements). Which of the following most accurately identifies the two independent fetal complications and their respective mechanisms?

• A) Both the oligohydramnios and ductal constriction result from a single fetal mechanism: ibuprofen causes generalized fetal hypotension by suppressing prostaglandin-mediated peripheral vasodilation, reducing both renal perfusion (decreasing urine output and amniotic fluid) and cardiac output (causing ductal constriction from reduced blood flow through the right heart); correcting fetal blood pressure with betamethasone (a corticosteroid) will resolve both findings simultaneously.
• B) The oligohydramnios is caused by ibuprofen crossing the placenta and inhibiting aquaporin-2 (AQP2, a water channel in the collecting duct) channels in the fetal kidney's collecting duct, preventing water reabsorption and paradoxically causing massive urinary water loss; the ductal constriction is caused by ibuprofen inhibiting COX-2 specifically in ductal smooth muscle, producing thromboxane A2 (TXA2) accumulation that constricts the vessel.
• C) The oligohydramnios reflects ibuprofen-induced placental COX-2 inhibition reducing placental prostaglandin production, causing placental vasoconstriction that reduces uteroplacental blood flow and limits amniotic fluid exchange across the placenta; the ductal constriction reflects ibuprofen-induced reduction of fetal cardiac PGI2 (prostacyclin) causing right ventricular wall tension overload from increased afterload.
• D) The two complications arise through two mechanistically independent pathways: (1) oligohydramnios from fetal renal prostaglandin suppression — ibuprofen crosses the placenta and inhibits COX-dependent prostaglandin synthesis in the fetal kidney, reducing prostaglandin-mediated fetal renal blood flow and GFR (glomerular filtration rate), decreasing fetal urine output (the primary source of amniotic fluid from mid-pregnancy); (2) ductal constriction from loss of PGE2 (prostaglandin E2)-mediated vasodilation of the ductus arteriosus via EP4 (prostaglandin E receptor subtype 4) receptors in ductal smooth muscle, which at 30 weeks is a high-risk period for premature ductal constriction; both risks were identified in the FDA (US Food and Drug Administration) Drug Safety Communication update and contraindication for NSAID use from 20 weeks onward.
• E) Both complications are caused by a single pharmacokinetic mechanism: ibuprofen accumulates in fetal amniotic fluid after placental transfer because fetal kidneys cannot conjugate ibuprofen to its glucuronide metabolite, causing toxic fetal amniotic fluid ibuprofen concentrations that directly damage the ductal smooth muscle and suppress renal tubular urine production through a non-prostaglandin cytotoxic mechanism.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Ibuprofen is immediately discontinued. Seventy-two hours later, repeat obstetric ultrasound shows an AFI of 7.8 cm (improved from 4.1 cm) and fetal cardiac Doppler shows resolution of the ductal constriction with normal ductal flow pattern. The patient is relieved and asks her obstetrician what these findings mean and whether her baby is at risk of permanent harm. Which of the following most accurately explains the expected recovery of both fetal complications and the mechanism of reversibility?

• A) Both the oligohydramnios and ductal constriction have improved because NSAID-induced fetal complications are caused by reversible pharmacodynamic prostaglandin suppression rather than by structural organ damage: once ibuprofen is cleared from the maternal and fetal circulations (within hours to days given ibuprofen's short plasma half-life of 1.8 to 2 hours), fetal COX enzyme activity recovers, PGE2 synthesis in both the fetal kidney and ductal smooth muscle resumes, fetal urine output normalizes restoring amniotic fluid, and the ductus arteriosus re-dilates; provided the duration of exposure was limited and no severe sustained ductal constriction occurred, permanent fetal harm is unlikely in this case.
• B) Both complications have improved because ibuprofen was metabolized by the fetal liver into a non-toxic hydroxylated metabolite (2-hydroxyibuprofen) that competes with unconjugated ibuprofen for EP4 receptor binding in ductal smooth muscle and renal tubular cells, producing competitive antagonism at the receptor level rather than complete blockade; the 72-hour recovery period allowed 2-hydroxyibuprofen to accumulate sufficiently to restore prostaglandin receptor signaling despite ongoing COX inhibition.
• C) The oligohydramnios has improved because the fetus began compensatory polyuria (excess urine output) mediated by upregulation of AVP (arginine vasopressin, also called antidiuretic hormone) receptors in the collecting duct; the ductal constriction has improved because sympathetic nervous system activation from fetal stress caused norepinephrine-mediated ductal smooth muscle relaxation through beta-2 adrenergic receptors; neither mechanism involves prostaglandin recovery.
• D) Both complications are consistent with permanent fetal structural injury that will require neonatal intervention: the 72-hour improvement in AFI and ductal Doppler reflects compensatory placental mechanisms masking ongoing fetal organ damage; the obstetrician should counsel the patient that immediate delivery by cesarean section is required to allow ex utero neonatal resuscitation before permanent renal and cardiac injury becomes irreversible.
• E) The recovery of both complications indicates that the ibuprofen was not actually the cause; true ibuprofen-induced fetal renal and ductal complications are irreversible and do not improve within 72 hours of drug cessation; the spontaneous improvement confirms that both findings were imaging artifacts caused by fetal positioning during the first ultrasound examination rather than true pathological changes.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. The fetal complications have resolved. The patient still has significant low back pain at 30 weeks and asks what she can safely take for the remaining 10 weeks of her pregnancy. She specifically asks whether any NSAID is safe at this stage, and what the safest oral analgesic is. Which of the following most accurately advises on the appropriate analgesic choice for the remainder of her pregnancy and explains the pharmacological rationale?

• A) Naproxen 250 mg twice daily is safe from 30 to 36 weeks because naproxen's long half-life of 12 to 17 hours provides sustained maternal analgesia with less frequent peak fetal drug concentrations than short-acting ibuprofen; the lower peak-to-trough ratio of naproxen reduces fetal renal and ductal prostaglandin suppression, making it appropriate for the late second trimester period before the absolute third-trimester contraindication begins at 36 weeks.
• B) Low-dose aspirin (81 mg/day) is the only NSAID safe throughout the third trimester at this dose because aspirin's irreversible platelet COX-1 acetylation does not affect fetal renal or ductal prostaglandin synthesis — platelet COX-1 is not expressed in fetal renal or ductal tissue and aspirin's pharmacological effect is therefore entirely platelet-restricted, with no fetal organ prostaglandin suppression at antiplatelet doses.
• C) Celecoxib 100 mg daily is safe in the third trimester because its selective COX-2 inhibition does not affect fetal ductal COX-1-dependent PGE2 synthesis, which is exclusively responsible for ductal patency at 30 weeks; fetal renal prostaglandins at this gestational age are also COX-1-derived and therefore unaffected by celecoxib's COX-2 selectivity.
• D) No analgesic is safe for musculoskeletal pain in pregnancy; the patient should be counseled that all analgesics including acetaminophen, NSAIDs, and opioids carry unacceptable fetal risks from 30 weeks onward and that pain management in the third trimester requires non-pharmacological approaches exclusively, with pharmacological analgesia reserved for labor only.
• E) Acetaminophen (paracetamol) at standard doses (325 to 650 mg every 4 to 6 hours as needed, maximum 3 g/day) is the recommended analgesic for the remainder of her pregnancy; acetaminophen does not inhibit COX-1 in fetal renal or ductal tissue at therapeutic doses and does not carry the fetal renal or ductal risks associated with NSAIDs; all NSAIDs — regardless of agent, dose, or COX selectivity — are contraindicated from 20 weeks of gestation onward due to fetal renal dysfunction and ductal constriction risk, and their use should not be resumed for any pain indication for the remainder of this pregnancy.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. The patient asks why the urgent care prescriber did not know ibuprofen was contraindicated in late pregnancy, and whether there are systemic safeguards to prevent this from happening to other patients. Her obstetrician explains the regulatory context. Which of the following most accurately describes the FDA regulatory guidance that applies to NSAID prescribing in pregnancy and the clinical implication for clinicians who may prescribe NSAIDs to women of reproductive age?

• A) No FDA regulatory guidance addresses NSAID use in pregnancy; the pregnancy contraindication for NSAIDs was established only through case reports in the medical literature without regulatory action, and clinicians are expected to identify the risk independently from primary literature rather than from FDA-mandated label warnings.
• B) The FDA requires NSAID labels to state that these drugs are contraindicated throughout all trimesters of pregnancy; this absolute contraindication was established in 2004 following the rofecoxib withdrawal, and applies equally to all gestational ages from conception onward; clinicians who prescribe any NSAID to a pregnant patient at any gestational age are in violation of the FDA prescribing restriction.
• C) The FDA issued a Drug Safety Communication in 2020 warning that NSAID use at or after 20 weeks of gestation may cause fetal renal dysfunction leading to oligohydramnios; this updated the previous third-trimester-only warning to begin at 20 weeks; the updated guidance requires prescribers to avoid NSAIDs from 20 weeks onward, or if use cannot be avoided after 20 weeks, to perform serial ultrasound monitoring of amniotic fluid volume; this case illustrates the failure to screen for pregnancy at a point of care before prescribing an NSAID.
• D) The FDA has designated all NSAIDs as Pregnancy Category X drugs (drugs contraindicated in pregnancy due to documented human fetal risk), and all NSAID prescriptions in the United States require mandatory pregnancy testing before dispensing; the urgent care's failure to perform mandatory pregnancy testing before prescribing ibuprofen represents a violation of federal dispensing regulations.
• E) The FDA has no authority to restrict NSAID prescribing in pregnancy because all currently available NSAIDs were approved before the current FDA pregnancy labeling system was established; the NSAID pregnancy risk data are therefore governed exclusively by state pharmacy board regulations rather than FDA label guidance, and vary by state.

17. [CASE 5 — QUESTION 1] A 61-year-old man with bipolar I disorder (a mood disorder with episodes of mania and depression) has been stable on lithium carbonate 1,200 mg daily for 8 years, with serum lithium levels consistently between 0.85 and 0.95 mEq/L (therapeutic range 0.6–1.2 mEq/L). He presents to his psychiatrist with an acute gout flare (intense joint inflammation from uric acid crystal deposition) in his right first metatarsophalangeal joint (the large toe joint). He tried colchicine (a gout medication that inhibits neutrophil migration) but could not tolerate the GI side effects. His rheumatologist recommends a short course of an NSAID (non-steroidal anti-inflammatory drug). His renal function is normal (eGFR 74 mL/min/1.73m²). Which of the following correctly identifies which NSAID has the least expected effect on lithium levels and explains the mechanism of the differential risk?

• A) Indomethacin 50 mg three times daily has the least effect on lithium levels among NSAIDs because its potent COX-2 (cyclooxygenase-2) inhibition selectively suppresses aldosterone synthesis in adrenal zona glomerulosa cells, simultaneously increasing renal potassium excretion and decreasing sodium (and lithium) reabsorption in the collecting duct, resulting in lithiuresis (increased lithium clearance) rather than lithium retention.
• B) Sulindac has the least expected effect on lithium levels among commonly used NSAIDs because its active sulfide metabolite is selectively re-oxidized to the inactive sulfone form in renal tissue, resulting in lower concentrations of active drug at renal prostaglandin-synthesizing cells; this relative renal prostaglandin sparing produces less enhancement of renal sodium (and parallel lithium) reabsorption compared to indomethacin (which has the greatest renal prostaglandin suppression and the highest lithium-raising effect among NSAIDs).
• C) Naproxen 500 mg twice daily has the least effect on lithium levels because naproxen's long half-life of 12 to 17 hours provides sustained but sub-maximal renal prostaglandin inhibition; the extended half-life allows renal prostaglandin synthesis to recover partially between doses, resulting in intermittent rather than continuous renal sodium (and lithium) retention, reducing the net increase in lithium levels compared to shorter-acting agents.
• D) Celecoxib 200 mg daily has the least effect on lithium levels because its selective COX-2 inhibition does not affect the renal tubular prostaglandin E2 (PGE2) that regulates renin release from juxtaglomerular cells, since juxtaglomerular cell renin secretion is exclusively regulated by COX-1-derived prostaglandins; celecoxib therefore does not reduce prostaglandin-dependent renin release and does not alter sodium or lithium clearance.
• E) Ibuprofen 400 mg three times daily has the least effect on lithium levels because ibuprofen's competitive reversible COX-1 inhibition produces only partial lithium retention during peak plasma levels and allows complete lithium clearance to resume during trough periods between doses; the partial nature of competitive inhibition produces a smaller net lithium level increase than agents with more sustained or irreversible mechanisms.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. Sulindac is prescribed for a 7-day course for his acute gout flare. The psychiatrist counsels him on monitoring requirements. Which of the following most accurately describes the appropriate lithium monitoring schedule for this patient during and after sulindac use, and the symptoms that should prompt immediate evaluation?

• A) No lithium monitoring is required during sulindac use because sulindac's renal-sparing properties completely eliminate any effect on lithium clearance; monitoring is only required when indomethacin or naproxen are used, not with sulindac; the patient should resume his normal every-3-months lithium monitoring schedule without any additional checks.
• B) A single lithium level should be checked 2 weeks after completing the 7-day course of sulindac, because the effect of NSAIDs on lithium levels reaches its maximum at approximately 14 days after initiation and returns to baseline over 2 additional weeks after the drug is stopped; no monitoring during the course itself is needed because the lithium level rise during a 7-day course is always subclinical.
• C) The patient should monitor his lithium levels at home using point-of-care lithium testing devices, and should call his psychiatrist only if his lithium level exceeds 1.5 mEq/L; no scheduled office monitoring is required during the 7-day course because lithium toxicity from a 7-day NSAID course in a patient with normal renal function is vanishingly rare and does not justify laboratory testing.
• D) A lithium level should be checked within 5 to 7 days of initiating sulindac to detect any significant increase before the course ends; a second level should be checked approximately 5 to 7 days after sulindac is completed, because stopping the NSAID will allow renal lithium clearance to increase, potentially causing the lithium level to fall below the therapeutic range; symptoms that should prompt immediate evaluation include coarse tremor, confusion, ataxia (unsteady gait), slurred speech, or cardiac palpitations — all signs of lithium toxicity.
• E) Lithium monitoring is not needed during the 7-day sulindac course, but the patient should have his lithium level checked the morning before his next scheduled psychiatry appointment in 3 months; the most important instruction is to double his lithium dose during the 7 days of sulindac to compensate for the anticipated reduction in lithium levels caused by sulindac's renal prostaglandin-sparing natriuretic effect.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. On day 6 of sulindac therapy, his lithium level returns at 1.4 mEq/L (up from his baseline of 0.9 mEq/L). He is currently asymptomatic — no tremor, confusion, or GI symptoms. Sulindac is scheduled to be completed tomorrow (day 7). Which of the following represents the most appropriate clinical response to a lithium level of 1.4 mEq/L in an asymptomatic patient on the second-to-last day of sulindac?

• A) A lithium level of 1.4 mEq/L is near the upper end of the therapeutic range (0.6–1.2 mEq/L) and above it; given that sulindac will be completed tomorrow, the appropriate response is to stop sulindac one day early, hold the evening lithium dose tonight, recheck the lithium level in 24 to 48 hours after sulindac is stopped, and counsel the patient on early toxicity symptoms to watch for; the expected direction after sulindac cessation is that the lithium level will fall back toward his baseline as renal clearance recovers.
• B) A lithium level of 1.4 mEq/L in an asymptomatic patient represents an acceptable result well within the therapeutic range; no dose adjustment or early NSAID cessation is needed; the patient should complete his full 7-day course and recheck his lithium at his next scheduled appointment in 3 months; lithium monitoring during NSAID courses is a precautionary practice but does not require action unless symptoms develop.
• C) The patient should immediately present to the emergency department for IV hemodialysis (a kidney replacement procedure) because a lithium level of 1.4 mEq/L has crossed the toxic threshold of 1.3 mEq/L; even in asymptomatic patients, any lithium level above 1.3 mEq/L requires emergent renal clearance of lithium to prevent irreversible neurological damage.
• D) The lithium level of 1.4 mEq/L should prompt an immediate lithium dose reduction to 600 mg daily (half the current dose) and continuation of sulindac to complete the full 7-day course, because reducing the lithium dose will counteract the NSAID-mediated reduction in lithium clearance and restore the level to baseline range; stopping sulindac early is not appropriate when the gout flare may not yet be fully suppressed.
• E) The lithium level of 1.4 mEq/L represents an expected transient pharmacokinetic peak during NSAID co-administration that will spontaneously correct without any intervention; no action is needed because lithium levels above the therapeutic range are only clinically meaningful when accompanied by neurological symptoms; the patient should complete his sulindac course and the level will self-correct within 24 hours by normal renal clearance.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. The gout flare has resolved and lithium has returned to 0.88 mEq/L one week after sulindac completion. His rheumatologist recommends urate-lowering therapy with allopurinol (a xanthine oxidase inhibitor that reduces uric acid production) for gout prophylaxis to prevent future flares. The rheumatologist also wants to prescribe a low-dose NSAID daily during the initiation of allopurinol (standard practice to suppress mobilization flares that can occur as serum urate falls). Given this patient's lithium therapy, which of the following is the most appropriate recommendation for managing potential gout flares during allopurinol initiation?

• A) Daily low-dose naproxen 250 mg is the most appropriate choice during allopurinol initiation because naproxen's long half-life provides more sustained anti-inflammatory coverage than shorter-acting NSAIDs, and its modest CYP2C9 inhibitory activity causes only a small INR elevation; the once-daily dosing of allopurinol and naproxen simplifies the regimen and improves adherence.
• B) Daily low-dose indomethacin 25 mg is the standard prophylactic agent during allopurinol initiation because indomethacin's potency allows lower doses for anti-inflammatory prophylaxis, and lower doses cause proportionally lower lithium level elevation; the lithium monitoring schedule can remain unchanged during low-dose indomethacin prophylaxis because the effect is dose-proportional.
• C) Low-dose sulindac 100 mg daily is appropriate during allopurinol initiation because its relative renal-sparing property minimizes lithium level elevation; a standard monitoring schedule of every 3 months is adequate during long-term low-dose sulindac prophylaxis in a patient with a history of well-managed lithium toxicity.
• D) No anti-inflammatory prophylaxis is needed during allopurinol initiation in patients on lithium because the risk of lithium toxicity from any NSAID outweighs the benefit of gout flare suppression; allopurinol should be started without prophylaxis and breakthrough flares treated with corticosteroids only.
• E) Low-dose colchicine (0.6 mg once or twice daily) is the preferred anti-inflammatory prophylactic agent during allopurinol initiation for this patient because colchicine does not interact with lithium through any prostaglandin-renal mechanism; it suppresses gout flares through inhibition of microtubule polymerization in neutrophils (preventing the inflammatory response to uric acid crystals) without affecting renal prostaglandin synthesis, sodium handling, or lithium clearance; colchicine's GI side effects at prophylactic doses are generally mild and dose-dependent, and if he previously had intolerance at treatment doses (typically 1.2 mg at onset then 0.6 mg 1 hour later), he should tolerate the lower prophylactic dose.

21. [CASE 6 — QUESTION 1] A 67-year-old woman with alcoholic cirrhosis (Child-Pugh B severity, a scoring system indicating moderate cirrhosis severity) and moderate ascites (fluid in the abdominal cavity) is admitted to hospital for management of her liver disease. She also has chronic low back pain. A consultant orthopedic surgeon, reviewing her chart, prescribes diclofenac 75 mg twice daily without noticing her liver disease diagnosis. Her hepatologist discovers the order before it is dispensed. Which of the following most accurately explains why diclofenac is particularly inappropriate for this patient, identifying both the hepatic and renal mechanisms of risk?

• A) Diclofenac is inappropriate solely because of a pharmacokinetic problem: diclofenac is extensively hepatically metabolized by CYP2C9 and CYP3A4, and Child-Pugh B cirrhosis reduces hepatic CYP enzyme activity by approximately 80%, causing diclofenac to accumulate to 5-fold higher plasma concentrations with proportionally greater systemic toxicity; the renal risk of diclofenac in cirrhosis is negligible because cirrhotic kidneys produce compensatory excess prostaglandins that buffer NSAID-mediated renal vasoconstriction.
• B) Diclofenac is inappropriate because it is the NSAID most likely to cause GI variceal (related to esophageal varices, enlarged veins from portal hypertension) bleeding through a specific COX-2-mediated pathway that increases portal venous pressure; the hepatic and renal risks of diclofenac are not specific to this drug and are shared equally by all NSAIDs; topical diclofenac should be avoided because its local anti-inflammatory effects on abdominal wall musculature would paradoxically increase portal venous resistance.
• C) Diclofenac carries two distinct categories of risk in this patient: (1) hepatic risk — diclofenac's CYP2C9/CYP3A4-mediated formation of a reactive acyl glucuronide metabolite triggers immune-mediated hepatocellular injury in susceptible patients; in a patient with Child-Pugh B cirrhosis, reduced hepatic metabolic reserve lowers the threshold for serious hepatotoxicity; and (2) renal risk — in cirrhosis with portal hypertension and ascites, RAAS and sympathetic nervous system activation render renal perfusion critically dependent on prostaglandin-mediated afferent arteriolar vasodilation; diclofenac's renal prostaglandin suppression in this state can precipitate AKI and hepatorenal syndrome even from a single dose; both risks are contraindications to diclofenac use in this patient.
• D) Diclofenac is inappropriate only because of its cardiovascular risk profile: its mixed COX-1/COX-2 inhibition with relative COX-2 predominance at standard doses suppresses endothelial PGI2 (prostacyclin) without proportionally suppressing platelet TXA2, creating a prothrombotic vascular environment; in cirrhotic patients with portal hypertension, this thrombogenic state can cause acute portal vein thrombosis (blood clot in the portal vein), precipitating fulminant hepatic failure; neither hepatotoxicity nor renal prostaglandin suppression are clinically meaningful risks at the 75 mg twice daily dose.
• E) Diclofenac is inappropriate because cirrhosis causes accumulation of unbound diclofenac in the aqueous ascitic fluid; the drug distributes into ascites and is then slowly released back into systemic circulation, creating an extended-release reservoir that maintains plasma diclofenac concentrations 3 to 4 times higher than in non-cirrhotic patients; this pharmacokinetic ascites-reservoir effect applies equally to all NSAIDs and is the primary reason all NSAIDs are avoided in patients with ascites.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. The diclofenac order is cancelled by the hepatologist. The patient still requires analgesic therapy for her back pain. Which of the following represents the most appropriate analgesic strategy for a patient with Child-Pugh B cirrhosis and ascites?

• A) Ibuprofen 400 mg as needed (maximum twice daily) is appropriate because ibuprofen's short half-life of 1.8 to 2 hours minimizes cumulative renal prostaglandin suppression in cirrhotic patients; the brief window of prostaglandin inhibition between doses allows full renal prostaglandin recovery before the next dose, preventing AKI; this intermittent low-dose strategy is endorsed by hepatology guidelines as a safe NSAID option in Child-Pugh B patients.
• B) Acetaminophen (paracetamol) at a reduced dose — maximum 2 g/day in a patient with active liver disease or a history of heavy alcohol use — is generally the preferred analgesic in stable cirrhotic patients because it does not suppress renal prostaglandins, does not cause GI mucosal erosion, does not worsen platelet dysfunction already impaired by hypersplenism, and at reduced doses does not produce the NAPQI (N-acetyl-p-benzoquinone imine, a toxic metabolite) accumulation that causes direct hepatocellular injury; acetaminophen is safer than NSAIDs in this population when used at appropriate doses.
• C) Morphine 5 mg as needed every 4 to 6 hours is the preferred analgesic because all NSAIDs and acetaminophen are absolutely contraindicated in Child-Pugh B cirrhosis; opioids are the only safe analgesic class in advanced liver disease because they are not hepatically metabolized and do not produce hepatotoxic metabolites; opioid-induced precipitating hepatic encephalopathy is a myth not supported by clinical evidence.
• D) No analgesic is appropriate for this patient given her Child-Pugh B cirrhosis; pain management in decompensated cirrhosis requires transfer to a tertiary hepatology center where specialized analgesic protocols can be developed with input from hepatology, pain medicine, and palliative care; prescribing any analgesic in a community hospital setting for this patient represents an unacceptable risk.
• E) Naproxen sodium 220 mg (OTC dose) as needed once daily is appropriate because at this minimal OTC dose, naproxen does not achieve plasma concentrations sufficient to inhibit renal prostaglandin synthesis in cirrhotic patients; renal prostaglandin inhibition by NSAIDs requires concentrations achieved only at prescription doses (500 mg twice daily), making OTC-dose naproxen safe in compensated and decompensated cirrhosis.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. Acetaminophen 500 mg four times daily (2 g/day) is started. Two weeks later, follow-up LFTs (liver function tests) show ALT (alanine aminotransferase, a liver enzyme) 148 U/L (2.6× ULN; upper limit of normal 56 U/L). Her baseline ALT on admission 4 weeks ago was 102 U/L (1.8× ULN), reflecting her underlying alcoholic hepatitis. Bilirubin and INR (international normalized ratio) are unchanged from admission. She has been abstinent from alcohol since admission. Which of the following most accurately guides interpretation of the ALT rise and the appropriate clinical response?

• A) The ALT rise to 2.6× ULN confirms acetaminophen toxicity; in cirrhotic patients, even the 2 g/day "reduced dose" is too high and produces NAPQI (N-acetyl-p-benzoquinone imine, a toxic acetaminophen metabolite) accumulation proportional to the residual CYP2E1 (cytochrome P450 2E1, the enzyme that produces NAPQI) enzyme activity; the appropriate response is immediate N-acetylcysteine (NAC, the antidote for acetaminophen toxicity) infusion to replenish glutathione, followed by permanent discontinuation of all acetaminophen.
• B) The ALT rise reflects normal disease progression in alcoholic hepatitis and is not related to acetaminophen; the dose of 2 g/day is entirely safe in cirrhosis and ALT monitoring while on acetaminophen is not necessary; the patient should continue 2 g/day indefinitely without further LFT surveillance.
• C) The ALT rise to 2.6× ULN exceeds the monitoring threshold of 2× ULN established for acetaminophen use in cirrhosis; acetaminophen must be immediately stopped and permanently discontinued, and the patient switched to a low-dose opioid (tramadol 25 mg as needed) as the only remaining safe analgesic in cirrhosis after acetaminophen hepatotoxicity is confirmed.
• D) An ALT of 2.6× ULN represents a modest increase from her baseline of 1.8× ULN in a patient with underlying alcoholic hepatitis; differentiating acetaminophen hepatotoxicity from disease progression requires clinical judgment: typical acetaminophen DILI (drug-induced liver injury) at therapeutic doses in cirrhosis produces more pronounced transaminase elevation (often greater than 5× ULN) and is accompanied by bilirubin rise and coagulopathy; the absence of bilirubin and INR worsening makes disease progression or fluctuation of underlying alcoholic hepatitis more likely than acetaminophen toxicity at this dose; a reasonable approach is to continue current management, ensure abstinence is confirmed, and recheck LFTs in 1 to 2 weeks.
• E) The ALT rise confirms that reduced-dose acetaminophen (2 g/day) is contraindicated in all cirrhotic patients regardless of severity; acetaminophen should be immediately replaced with tramadol (a weak opioid) plus celecoxib 100 mg daily as the most hepatically safe analgesic combination; celecoxib at this dose does not affect hepatic CYP enzyme activity or produce reactive metabolites in cirrhotic patients.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. She is preparing for discharge. LFTs have been stable, and her back pain continues to limit her mobility. Her hepatologist discusses long-term analgesic options with her. She asks whether topical diclofenac gel might be an option since "it's just on the skin." Which of the following most accurately advises on whether topical diclofenac is appropriate for this patient and why?

• A) Topical diclofenac 1% gel is a reasonable option for localized musculoskeletal pain in this patient; at systemic bioavailability of approximately 6 to 10% of an equivalent oral dose, the systemic diclofenac exposure is dramatically reduced, substantially lowering the renal prostaglandin suppression that makes oral NSAIDs dangerous in cirrhosis with ascites; the hepatic exposure to the reactive acyl glucuronide metabolite is also proportionally reduced, making the hepatotoxicity risk substantially lower than with oral diclofenac; topical diclofenac remains a preferable choice to escalating acetaminophen above 2 g/day or introducing systemic NSAIDs, provided the patient applies it to a non-abdominal skin area and is monitored appropriately.
• B) Topical diclofenac is contraindicated in cirrhosis because all diclofenac — regardless of formulation or route — produces identical systemic plasma concentrations; topical application does not reduce bioavailability relative to oral administration, because extensive dermal capillary networks adjacent to skin application sites provide equivalent systemic delivery as the GI mucosa does for oral formulations.
• C) Topical diclofenac is not appropriate because it contains propylene glycol (a solvent in topical gel formulations) as an excipient that undergoes hepatic metabolism to toxic lactaldehyde; in Child-Pugh B cirrhosis, reduced hepatic clearance of propylene glycol metabolites causes accumulation of lactaldehyde, producing the same pattern of hepatocellular injury as the diclofenac acyl glucuronide metabolite.
• D) Topical diclofenac is not a viable option for this patient because transdermal drug absorption is significantly increased in patients with ascites; the fluid-swollen subcutaneous tissue in a patient with moderate ascites enhances skin permeability and produces systemic bioavailability equivalent to 80% of an oral dose, eliminating the safety advantage of topical administration.
• E) Topical diclofenac is inappropriate for all patients with liver disease because the FDA has issued a contraindication for topical NSAID use in all hepatic impairment categories (Child-Pugh A, B, and C), citing concerns that skin application bypasses hepatic first-pass metabolism and delivers higher concentrations of unreacted diclofenac to systemic circulation than oral administration, which undergoes first-pass conversion to the less toxic sulfoxide metabolite.

25. [CASE 7 — QUESTION 1] A 58-year-old man with rheumatoid arthritis (RA, a chronic autoimmune joint disease) has been treated with weekly oral methotrexate (MTX) 20 mg for 3 years with good disease control and stable complete blood counts. Six weeks ago, a physician covering for his regular rheumatologist prescribed celecoxib 200 mg twice daily for a pain flare, and the patient independently began taking ibuprofen 400 mg as needed (2 to 3 times per week) from his medicine cabinet for additional relief. He was not told that taking two NSAIDs simultaneously was problematic. He now presents with oral mucositis (painful mouth sores), fatigue, and ecchymoses (bruising). Laboratory results: WBC (white blood cell count) 1,600/μL (normal >4,000), platelets 52,000/μL (normal >150,000), creatinine 1.6 mg/dL (baseline 0.9 mg/dL). Which of the following most accurately identifies all the pharmacological contributors to his clinical presentation?

• A) His presentation reflects celecoxib-specific myelosuppression (bone marrow suppression): celecoxib's selective COX-2 inhibition in hematopoietic progenitor cells suppresses prostaglandin-dependent erythroid and myeloid differentiation, causing pancytopenia; ibuprofen is not contributing because it does not inhibit hematopoietic COX-2; MTX is not contributing because his presentation is inconsistent with MTX toxicity at the 20 mg/week dose.
• B) His presentation reflects ibuprofen-induced aplastic anemia from direct bone marrow toxicity: ibuprofen's reactive metabolite (ibuprofen acyl glucuronide) accumulates in bone marrow progenitor cells in patients taking concurrent celecoxib, because celecoxib inhibits the UGT (UDP-glucuronosyltransferase) enzyme responsible for ibuprofen glucuronide excretion from marrow cells; the combined accumulation causes direct progenitor cell DNA damage; MTX is not involved because 20 mg/week is below the myelosuppressive dose threshold.
• C) His presentation is caused exclusively by MTX toxicity from his regular 20 mg/week dose, which has reached a toxic threshold after 3 years of accumulation as hepatic polyglutamate stores (the intracellular stored form of MTX) have reached a level causing systemic folate depletion; neither celecoxib nor ibuprofen are contributing because COX-2 inhibitors do not interact with MTX, and ibuprofen at 400 mg as-needed does not reach plasma concentrations sufficient to inhibit OAT (organic anion transporter)-mediated MTX renal excretion.
• D) His presentation reflects SSRI-like platelet serotonin depletion from celecoxib: celecoxib's COX-2 inhibition in platelet-producing megakaryocytes (large bone marrow cells that produce platelets) depletes platelet serotonin through a pathway involving thromboxane A2 (TXA2) deficiency; ibuprofen compounds this by irreversibly acetylating platelet COX-1; the combination causes immune-mediated platelet destruction; MTX polyglutamate accumulation in megakaryocytes is a separate contributing mechanism.
• E) The presentation reflects MTX toxicity precipitated by two simultaneous NSAID contributions to impaired renal MTX excretion: both celecoxib and ibuprofen reduce renal GFR (glomerular filtration rate) through renal prostaglandin suppression (celecoxib via COX-2, ibuprofen via COX-1 and COX-2), reducing filtered MTX load; ibuprofen additionally competitively inhibits OAT (organic anion transporter)-mediated MTX tubular secretion; together they have elevated MTX plasma concentrations sufficiently above the safe weekly exposure to produce the classic MTX toxicity syndrome of mucositis and myelosuppression; concurrent use of two NSAIDs by the same patient (celecoxib plus ibuprofen) is never appropriate and compounds the interaction.

26. [CASE 7 — QUESTION 2] Continuing with the same patient. MTX toxicity from impaired renal excretion is confirmed. Both NSAIDs are stopped immediately. His rheumatologist is called. Which of the following most accurately describes the mechanism of leucovorin (folinic acid) as a rescue agent for MTX toxicity, and explains why it can reverse myelosuppression without simply antagonizing MTX's anti-inflammatory effect in the joints?

• A) Leucovorin reverses MTX toxicity by competitively binding to dihydrofolate reductase (DHFR, the enzyme MTX inhibits) with higher affinity than MTX, displacing MTX from its enzyme target in all cell types simultaneously; because leucovorin has a shorter half-life than MTX at toxic plasma concentrations, the competitive displacement is transient and selective for rapidly dividing cells (marrow progenitors) rather than synovial cells (which divide more slowly), preserving the anti-inflammatory effect selectively.
• B) Leucovorin reverses MTX toxicity by activating hepatic CYP3A4 (cytochrome P450 3A4) enzymes to accelerate MTX oxidative metabolism to its inactive 7-hydroxy metabolite, reducing circulating MTX plasma concentrations; because synovial cell MTX polyglutamates (the intracellular stored form) are not affected by accelerated plasma MTX clearance, the intra-articular anti-inflammatory effect is preserved while systemic toxicity is reversed.
• C) Leucovorin is a reduced, pre-formed folate (5-formyl tetrahydrofolate) that bypasses the DHFR (dihydrofolate reductase) step that MTX inhibits; it directly provides the reduced folate cofactors required for thymidylate synthesis and purine synthesis in rapidly dividing cells without needing to be processed by DHFR; this allows DNA synthesis to resume in myelosuppressed bone marrow progenitor cells, reversing pancytopenia; because leucovorin is given parenterally after MTX has been stopped, it does not meaningfully antagonize the residual anti-inflammatory polyglutamate effect in synovial tissue.
• D) Leucovorin reverses MTX toxicity by chelating (chemically binding to) the reactive MTX polyglutamate metabolites in bone marrow progenitor cells, forming an inert leucovorin-MTX polyglutamate complex that is excreted renally without causing further DNA synthesis inhibition; the chelation is cell-type specific because marrow progenitors express a leucovorin-MTX chelation enzyme (LMCE) not present in synovial fibroblasts, preserving the anti-inflammatory polyglutamate effect selectively.
• E) Leucovorin reverses MTX toxicity by stimulating thymidine kinase (TK, an enzyme in the DNA salvage pathway) activity in bone marrow progenitor cells; TK-mediated production of thymidine monophosphate (TMP) from exogenous thymidine bypasses the thymidylate synthase step that MTX indirectly inhibits; this TK-dependent DNA synthesis rescue is restricted to rapidly dividing cells that express high TK activity, preserving MTX's anti-inflammatory effect in slowly dividing synovial pannus cells.

27. [CASE 7 — QUESTION 3] Continuing with the same patient. After leucovorin rescue, his CBC normalizes over 2 weeks and creatinine returns to 1.0 mg/dL (near baseline). His rheumatologist restarts MTX at a reduced dose of 15 mg/week. The patient will likely need ongoing anti-inflammatory analgesic support for his RA. His rheumatologist wants to establish a safe co-prescribing framework. Which of the following most accurately describes the safest approach to NSAID use in this patient who requires ongoing MTX therapy?

• A) No NSAID can ever be used concurrently with any dose of MTX in patients with RA; all NSAIDs inhibit OAT-mediated MTX renal excretion with equal potency regardless of dose or COX selectivity, making any NSAID use an absolute contraindication in all patients on any dose of weekly oral MTX; the only acceptable analgesic supplements to MTX in RA are acetaminophen and topical agents.
• B) If an NSAID is required for RA symptom management, it can be used cautiously at the lowest effective dose with close monitoring; some rheumatology guidelines recommend holding the NSAID for 24 to 48 hours around the weekly MTX dose to minimize the period of concurrent exposure when MTX plasma concentrations are highest and OAT inhibition most consequential; creatinine and CBC should be monitored more frequently than every 3 months whenever an NSAID is co-prescribed; two NSAIDs should never be taken simultaneously.
• C) Celecoxib is completely safe to combine with weekly MTX at any dose because celecoxib's selective COX-2 inhibition does not inhibit renal OAT transporters (which transport organic anions via a COX-1-dependent mechanism) and does not reduce renal GFR through prostaglandin suppression; celecoxib can be prescribed at full therapeutic doses without any additional monitoring beyond the standard MTX monitoring schedule.
• D) The safest approach is to permanently replace MTX with a biologic DMARD (disease-modifying antirheumatic drug, a class of targeted therapies for RA) such as adalimumab (an anti-TNF antibody), because the NSAID-MTX interaction will always be a risk as long as MTX is used; biologics have no interactions with NSAIDs and can be combined freely with any NSAID at any dose without OAT inhibition or renal prostaglandin concerns.
• E) The patient should be switched to high-dose ibuprofen (1,600 mg/day) as a DMARD alternative to MTX, because ibuprofen at high doses inhibits COX-2 sufficiently to suppress the inflammatory synovial pannus (the tissue driving RA joint destruction) through the same anti-inflammatory pathway as MTX; this allows elimination of MTX from the regimen, removing the OAT interaction risk entirely while providing equivalent disease control.

28. [CASE 7 — QUESTION 4] Continuing with the same patient. During the post-hospitalization review, it becomes clear that three preventable failures contributed to this event: (1) the covering physician prescribed celecoxib without knowing about the patient's MTX; (2) the patient was never counseled that taking additional OTC NSAIDs while on any prescription NSAID plus MTX was dangerous; (3) no pharmacist review caught the dual NSAID use. Which of the following most accurately identifies the most important patient-level pharmacological education point that would have prevented this specific adverse event?

• A) The patient should have been told that MTX is an immunosuppressant (a drug that weakens the immune system) and that any concurrent medication — including OTC drugs — requires explicit prescriber approval before use; broad immunosuppressant counseling would have prompted him to ask before taking ibuprofen, regardless of whether he understood the specific OAT-MTX renal interaction.
• B) The patient should have been provided with a complete printed list of all drugs that are absolutely contraindicated with MTX at any dose; ibuprofen and celecoxib are on this absolute contraindication list, and the pharmacy should have refused to dispense celecoxib to a patient whose medication record included MTX, as this represents a pharmacy dispensing error.
• C) The patient should have been enrolled in a medication monitoring program with weekly pharmacist phone calls throughout all MTX therapy, because the MTX-NSAID interaction requires continuous real-time pharmacovigilance that cannot be delegated to the patient or prescribers; the adverse event confirms that MTX cannot be safely prescribed outside of a specialized rheumatology pharmacy monitoring network.
• D) The patient should have been specifically counseled that NSAIDs — including OTC ibuprofen, naproxen, and aspirin at analgesic doses — reduce the kidney's ability to excrete MTX, raising MTX levels to potentially toxic concentrations; he should never take any NSAID (prescription or OTC) without first confirming with his rheumatologist; this single piece of explicit, drug-class-specific education would have prevented him from self-medicating with ibuprofen while already on a prescription NSAID plus weekly MTX, addressing the root cause of the event.
• E) The patient should have been counseled to check his CBC (complete blood count) weekly at home using a fingerstick point-of-care test, because the MTX-NSAID interaction produces bone marrow toxicity before mucositis symptoms appear; early CBC changes would have prompted him to stop both NSAIDs before clinically significant myelosuppression developed, and home CBC monitoring is now considered standard of care for all patients on MTX above 15 mg/week.